Twenty-four quassinoids isolated from Eurycoma longifolia Jack were investigated for their cytotoxicity against a panel of four different cancer cell lines, which includes three murine cell lines [colon 26-L5 carcinoma (colon 26-L5), B16-BL6 melanoma (B16-BL6), Lewis lung carcinoma (LLC)] and a human lung A549 adenocarcinoma (A549) cell line. Among the tested compounds, eurycomalactone (9) displayed the most potent activity against all the tested cell lines; colon 26-L5 (IC 50 = 0.70 μM), B16-BL6 (IC 50 = 0.59 μM), LLC (IC 50 = 0.78 μM), and A549 (IC 50 = 0.73 μM). These activities were comparable to clinically used anticancer agent doxorubicin (colon 26-L5, IC 50 = 0.76 μM; B16-BL6, IC 50 = 0.86 μM; LLC, IC 50 = 0.80 μM; A549, IC 50 = 0.66 μM).
Cancer is the leading cause of death in the world [1] . In Japan, despite the implementation of the 3rd-term Comprehensive 10-year Strategy for Cancer Control (2004) (2005) (2006) (2007) (2008) (2009) (2010) (2011) (2012) (2013) by Japanese government and the enforcement of the Cancer Control Act (2007) by the Japanese Ministry of Health, Labour and Welfare, 343 thousand people died of cancer in the year 2008, and the number of cancer deaths project to increase further [2, 3] . Hence, a search for new alternatives for prevention and treatment of cancer is one of focus points to minimize this unwanted human mortality. As part of our project on discovery of novel anticancer agents from natural sources [4] , we observed that the 70% EtOH extract of Eurycoma longifolia Jack showed potent cytotoxicity against human HT-1080 fibrosarcoma cell line. Therefore, we carried out the detailed phytochemical investigation, and reported 24 quassinoids and their cytotoxic activity against the human HT-1080 fibrosarcoma cell line [5] . We found that some of the compounds such as 13,21-dihydroeurycomanone (1), 14,15β-dihydroxyklaineanone (5), eurycomalactone (9) , and 6αhydroxyeurycomalactone (11) showed highly potent activity against HT-1080 cell line, which were stronger than the positive controls used. This encouraged us to test these compounds further in other cancer cell lines and explore their structure activity relationship. In this paper, we report the cytotoxic activity of 24 quassinoids against a panel of four cancer cell lines.
In vitro cytotoxicity of the quassinoids isolated from E. longifolia Jack was examined against three murine cancer cell lines [colon 26-L5 carcinoma (colon 26-L5) [6] , B16-BL6 melanoma (B16-BL6) [7] , Lewis lung carcinoma (LLC) [8] , and a human lung A549 adenocarcinoma (A549) cancer cell line [9] . In this study, 5-fluorouracil (5-FU) and doxorubicin (Dox), clinically used anticancer agents [10] , were used as positive controls.
In eurycomanone-type quassinoids (1-3) and their derivative (4), some agents displayed the selective cytotoxicity against B16-BL6 and A549 cell lines (Table 1) . 13,21-Dihydroeurycomanone (1) possessing β-oriented hydroxyl group at C-14 was found to be stronger than α-oriented one (1>2), and the activity of 1 against A549 was stronger than positive control 5-FU. Likewise, the free hydroxyl groups at C-12 and C-15 were favorable for potency (1>3). The modification of rings-A,B as in 4 caused a loss of activity. 14,15β-Dihydroxyklaineanone (5) and 11-dehydroklaineanone (7) displayed the potent cytotoxicities against B16-BL6 and A549, and the mild cytotoxicities against colon 26-L5 and LLC among klaineanone-type quassinoids (5-8) ( Table 2 ). The compound without an α-hydroxyl substituent at C-6 displayed stronger cytotoxic activity (5>6). The orientation of hydroxyl group at C-12 was found to have a significant role for activity; 8 possessing β-oriented hydroxyl group was virtually inactive, while corresponding epimer with α-oriented hydroxyl group were dramatically active (7>8), and its IC 50 value were comparable to 5-FU against B-16-BL6 and A549 cell lines. Absence of 11,20-epoxy linkage in 5 compared to 1 also remarkably favors activity against colon 26-L5 and LLC (1<5).
Many of eurycomalactone-type quassinoids (9-21) and longilactone (22) had strong non-selective cytotoxicity against all the cell lines (Table 3 ). It was clear that the double bond between C-3 and C-4 was important. All the compounds possessing a double bond between C-3 and C-4 displayed dramatically strong activity than those of the Δ4(18) isomer, the 3,4-epoxide analogue, and the saturated derivative (13>15, 16>19, 17>18, 17>20). Meanwhile, eurycomalactones with the 2-keto group possessed stronger activity than those with the 2-hydroxyl group (9>13, 11>14, 16>17). Similarly compounds without any hydroxyl substituents on C-5 and C-6 showed enhanced activity (9>10, 9>11, 13>14). Furthermore, the absence of the conjugation extended to C-5(6) was favorable to the activity (9>16, 13>17). Among the tested compounds, eurycomalactone (9) displayed the most potent cytotoxic activity against all the four tested cell lines (colon 26-L5, IC 50 = 0.70 μM; B16-BL6, IC 50 = 0.59 μM; LLC, IC 50 = 0.78 μM; A549, IC 50 = 0.73 μM).
Laurycolactone A (23) and laurycolactone B (24) as laurycolactone-type quassinoids didn't show significant cytotoxic activity against all the cell lines ( Table 4 ). The weaker activity compared to corresponding eurycomalactone-type quassinoids suggested that the cyclohexenone ring of ring-A as in eurycomalactones was important for the cytotoxicity (9, 13>23; 16,  17>24) .
In summary, 24 quassinoids isolated from E. longifolia Jack were tested for the in vitro cytotoxic activity against four cancer cell lines. Eurycomanones showed selective cytotoxicity against B16-BL6, and A549. Klaineanones with a 12α-hydroxyl group without any substituent at C-6 showed potent activity against four tested cell lines. Eurycomalactones in general were active against all the tested cancer cell lines, and eurycomalactone (9) showed the most potent activity in all the tested cell lines. The activity of 9 were comparable to clinically used anticancer drug doxorubicin, and were stronger than a 5-FU. Moreover, 9 contains all the essential structural features required for enhanced activity such as presence of 2-and 7-keto groups, a double bond between C-3 and C-4 and without any substituent at C-5 or C-6. Natural Product Communications Vol. 5 (7) 2010 1011 (22), laurycolactone A (23), and laurycolactone B (24) were obtained from the 70% EtOH extract of stems of E. longifolia Jack [5] . Their purity was checked by the analytical TLC and the 1 H NMR spectrum.
Agents: 5-Fluorouracil was purchased from Tokyo Kasei Kogyo Co. Ltd. (Tokyo, Japan), and doxorubicin hydrochloride was from Kyowa Hakko Co. Ltd. (Tokyo, Japan). RPMI 1640 Medium was purchased from Nissui Pharmaceutical Co., Ltd. (Tokyo, Japan) α-Modified minimum essential medium (MEMα) and 25% glutaraldehyde solution were obtained from Wako Pure Chemicals Ind., Ltd. (Osaka, Japan). Sodium bicarbonate was purchased from Nacalai Tesque Inc. (Kyoto, Japan), and fetal bovine serum (FBS) was from Gibco BRL Products (Gaithersburg, MD, USA). Antibiotic antimycotic solution and 3-(4,5dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) were from Sigma-Aldrich Inc. (St. Louis, MO, USA), and crystal violet was from Nacalai Tesque
